OncoMatch/Clinical Trials/NCT06086457
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Is NCT06086457 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including PD-1 inhibitor and TP or PF regimen depended on investigator's choice. for esophageal neoplasms.
Treatment: TP or PF regimen depended on investigator's choice. · PD-1 inhibitor — The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently. On this basis, the investigators intend to conduct a prospective, multicenter phase III clinical trial to assess whether radiotherapy with concurrent chemotherapy and immunotherapy could further improve the survival of patients with metastatic esophageal cancer. Accompanied tissue samples, blood samples and urine samples will be analyzed by molecular biological detection (Including Whole Exome Sequencing and proteomics) to explore potential biomarkers for predicting outcomes, efficacy and toxicity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage IVB
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: thoracic radiation
No prior history of thoracic radiation
Cannot have received: chemotherapy
Received ... chemotherapy or other anti-tumor treatment before enrollment
Cannot have received: surgery
Exception: ostomy
Received surgery (except ostomy) ... before enrollment
Lab requirements
Blood counts
no significant abnormality in blood routine
Kidney function
no significant abnormality in kidney function
Liver function
no significant abnormality in liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify